Genome-wide Identification of M6A-associated Functional SNPs As Potential Functional Variants for Thyroid Cancer

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 Dec 7

PMID 34873468

Citations 12

Authors

Xianhui Ruan

Mengran Tian

Ning Kang

Weike Ma

Yu Zeng

Gaojian Zhuang

Wei Zhang

Guangwei Xu

Linfei Hu

Xiukun Hou

Wenjun Xie

Ming Gao

Yongjun Piao

Shicheng Guo

Xiangqian Zheng

Affiliations

Soon will be listed here.

Abstract

m6A methylation has been demonstrated to be one of the most important epigenetic regulation mechanisms in cell differentiation and cancer development especially m6A derived diagnostic and prognostic biomarkers have been identified in the past several years. However, systemic investigation to the interaction between germline single-nucleotide polymorphisms (SNPs) and m6A has not been conducted yet. In this study, we collected previous identified significant thyroid cancer associated SNPs from UKB cohort (358 cases and 407,399 controls) and ICR cohort (3,001 patients and 287,550 controls) and thyroid eQTL (sample size = 574 from GTEx project) and m6A-SNP (N = 1,678,126) were applied to prioritize the candidate SNPs. Finally, five candidate genes () were identified to be thyroid cancer associated m6A-related genetic susceptibility. Loss and gain function studies of m6A writer proteins confirm that ACSM5 is regulated by m6A methylation of mRNA. Moreover, ACSM5 is downregulated in thyroid cancer and inversely correlated with PTC malignancy and patient survival. Together, our study highlight mRNA-seq and m6A-seq double analysis provided a novel approach to identify cancer biomarkers and understanding the heterogeneity of human cancers.

Citing Articles

METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8.

Kang N, Zhao Z, Wang Z, Ning J, Wang H, Zhang W Int J Biol Sci. 2024; 20(9):3426-3441.

PMID: 38993572 PMC: 11234206. DOI: 10.7150/ijbs.84797.

Homozygous EPRS1 missense variant causing hypomyelinating leukodystrophy-15 alters variant-distal mRNA mA site accessibility.

Khan D, Ramachandiran I, Vasu K, China A, Khan K, Cumbo F Nat Commun. 2024; 15(1):4284.

PMID: 38769304 PMC: 11106242. DOI: 10.1038/s41467-024-48549-x.

Multidimensional data analysis revealed thyroiditis-associated TCF19 SNP rs2073724 as a highly ranked protective variant in thyroid cancer.

Ruan X, Liu Y, Wu S, Fu G, Tao M, Huang Y Aging (Albany NY). 2024; 16(7):6488-6509.

PMID: 38579171 PMC: 11042956. DOI: 10.18632/aging.205718.

m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer.

Cai L, Liu T, Hua H, Jiang X, Qian L BMC Endocr Disord. 2023; 23(1):271.

PMID: 38057752 PMC: 10699001. DOI: 10.1186/s12902-023-01510-3.

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer.

Ning J, Hou X, Hao J, Zhang W, Shi Y, Huang Y Cell Death Differ. 2023; 30(10):2265-2279.

PMID: 37648786 PMC: 10589295. DOI: 10.1038/s41418-023-01217-x.

References

Kim J, Gosnell J, Roman S . Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2019; 16(1):17-29. DOI: 10.1038/s41574-019-0263-x. View

Chen M, Wei L, Law C, Tsang F, Shen J, Cheng C . RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2017; 67(6):2254-2270. DOI: 10.1002/hep.29683. View

Wang Y, Feng S, Guo S, Wei W, Li D, Wang Y . Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. J Med Genet. 2013; 50(10):689-95. DOI: 10.1136/jmedgenet-2013-101687. View

Cabanillas M, McFadden D, Durante C . Thyroid cancer. Lancet. 2016; 388(10061):2783-2795. DOI: 10.1016/S0140-6736(16)30172-6. View

Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z . METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019; 18(1):142. PMC: 6790244. DOI: 10.1186/s12943-019-1065-4. View

Luo Z, Liu Z, Mao Y, Shu R, Fu L, Yang R . Cajanolactone A, a stilbenoid from cajanus cajan, prevents ovariectomy-induced obesity and liver steatosis in mice fed a regular diet. Phytomedicine. 2020; 78:153290. DOI: 10.1016/j.phymed.2020.153290. View

Patil D, Chen C, Pickering B, Chow A, Jackson C, Guttman M . m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016; 537(7620):369-373. PMC: 5509218. DOI: 10.1038/nature19342. View

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

10.

Wang X, Fu X, Zhang J, Xiong C, Zhang S, Lv Y . Identification and validation of mA RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. Cancer Cell Int. 2020; 20:203. PMC: 7260751. DOI: 10.1186/s12935-020-01283-y. View

11.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

12.

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

13.

Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S . Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018; 24(13):3059-3068. PMC: 6030480. DOI: 10.1158/1078-0432.CCR-18-0373. View

14.

Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R . Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid. 2013; 23(12):1532-40. PMC: 3868253. DOI: 10.1089/thy.2013.0102. View

15.

Visvanathan A, Patil V, Arora A, Hegde A, Arivazhagan A, Santosh V . Essential role of METTL3-mediated mA modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2017; 37(4):522-533. DOI: 10.1038/onc.2017.351. View

16.

Wang K, Jiang L, Zhang Y, Chen C . Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating mA Methylation on TCF1. Onco Targets Ther. 2020; 13:1605-1612. PMC: 7044742. DOI: 10.2147/OTT.S234751. View

17.

Gudmundsson J, Thorleifsson G, Sigurdsson J, Stefansdottir L, Jonasson J, Gudjonsson S . A genome-wide association study yields five novel thyroid cancer risk loci. Nat Commun. 2017; 8:14517. PMC: 5316879. DOI: 10.1038/ncomms14517. View

18.

Liu J, Eckert M, Harada B, Liu S, Lu Z, Yu K . mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018; 20(9):1074-1083. PMC: 6245953. DOI: 10.1038/s41556-018-0174-4. View

19.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson S . Promoter-bound METTL3 maintains myeloid leukaemia by mA-dependent translation control. Nature. 2017; 552(7683):126-131. PMC: 6217924. DOI: 10.1038/nature24678. View

20.

Zaccara S, Ries R, Jaffrey S . Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019; 20(10):608-624. DOI: 10.1038/s41580-019-0168-5. View